News und Analysen
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of
Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region
Orlando Health and Acadia Healthcare Company announced today that they have formed a joint venture designed to enhance and expand behavioral health services in the region.
This press release
Acadia Healthcare Forms Joint Venture With Orlando Health
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Orlando Health, one of Central Florida’s premier health systems. With Acadia’s partnership
Entdecke das Naturwunder: Egmont Honey Manuka Honig MGO 829+ UMF 20+ zum unschlagbaren Preis!
Entdecke die Luftfahrt neu: DJI Avata Explorer Combo jetzt zum unschlagbaren Angebot!
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too
HealthEquity Stock: Leading Health Savings Account Investment
HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open
Johnson & Johnson is as Cheap as it’s Going to Get
Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading
Med-tech stock Conmed dips ahead of big Q4 report...opportunity?
When Utica, NY-based medical technology company CONMED Corporation (NYSE:CNMD) reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
Hospital chain HCA Healthcare, Inc. (NYSE: HCA) has been working on a bullish base and even managed to post gains in a week when the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) pulled back.
Investors
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers Squibb Company (NYSE: BMY) is on a buying spree, announcing two acquisitions in less than a week.
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc.
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
BellRing Brands gets pumped on the Ozempic weight-loss trend
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly
Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split
For Walt Disney Co. (NYSE: DIS) shareholders, their brokerage statements haven’t exactly been the happiest place on earth. The stock has lagged the S&P 500 for the past 10 years, although it’s
Masimo, Medical Device Maker Drops on Q2 Guidance, Opportunity?
Shares of health monitoring technology maker Masimo Corporation (NASDAQ: MASI) dropped 24% to $114.30 last week due to a second-quarter performance warning. They are at their lowest level since
Zillow’s Stock Is Hot...The Housing Market Is Not
Up more than 70% this year, Zillow Group, Inc. (NASDAQ:ZG) is one of the hottest technology stocks — and yet it's not exactly making a big splash.
In a market focused on artificial intelligence
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel
German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet
MOUNTAIN VIEW und SAN FRANCISCO, KALIFORNIEN / ACCESSWIRE / 11. Mai 2023 / Die German International School of Silicon Valley (GISSV) wurde im Rahmen des von der Deutschen Industrie- und
Kombination aus TALVEY®▼ (talquetamab) und DARZALEX® (daratumumab) in subkutaner (s. c.) Formulierung zeigt tiefgreifendes und dauerhaftes Ansprechen bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom
Aktuelle Daten zeigen 100 Prozent Gesamtansprechrate, wobei 56 Prozent der Patienten bei wöchentlicher Verabreichung ein komplettes Ansprechen oder besser erreichten, was die Kombinierbarkeit des
Santhera’s LIONHEART-Studie mit AGAMREE® (Vamorolon) zeigt positive Topline-Ergebnisse und einzigartigen Mineralokorticoid-Rezeptor-Antagonismus
Pratteln, Schweiz, 1. Oktober 2024 – Santhera Pharmaceuticals (SIX: SANN) gibt das positive Ergebnis der LIONHEART-Studie bekannt, das die einzigartige Wirkung von Vamorolon auch als
CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) ist die erste Zelltherapie, die das Gesamtüberleben von Patienten mit multiplem Myelom bereits in der Zweitlinienbehandlung im Vergleich zu Standardtherapien signifikant verlängert
45-prozentige Verringerung des Sterberisikos durch cilta-cel im Vergleich zu Standardtherapien nach dreijähriger Nachbeobachtung in der bahnbrechenden CARTITUDE-4-Studie1
Die Daten wurden auf der